Chen L, Alexe G, Dharia NV, et al. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018;128(1):446-462. doi:10.1172/JCI90793
Fenteany G, Schreiber SL. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. Chem Biol. 1996;3(11):905-12.
Fenteany G, Schreiber SL. Lactacystin, proteasome function, and cell fate. J Biol Chem. 1998;273(15):8545-8.
Hahn CK, Ross KN, Warrington IM, et al. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A. 2008;105(28):9751-6. doi:10.1073/pnas.0710413105
Powers JT, Tsanov KM, Pearson DS, et al. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature. 2016;535(7611):246-51. doi:10.1038/nature18632
Cavalli M, Pan G, Nord H, et al. Allele-specific transcription factor binding to common and rare variants associated with disease and gene expression. Hum Genet. 2016;135(5):485-97. doi:10.1007/s00439-016-1654-x
Strazisar M, Cammaerts S, Ven K, et al. MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets. Mol Psychiatry. 2015;20(4):472-81. doi:10.1038/mp.2014.53
Frumm SM, Fan ZP, Ross KN, et al. Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. Chem Biol. 2013;20(5):713-25. doi:10.1016/j.chembiol.2013.03.020
Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308-23. doi:10.1158/2159-8290.CD-12-0418
Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279-84. doi:10.1038/ng.2529